Midwest BioResearch introduces microAmes
screen test

Midwest BioResearch, LLC (MBR), an outsourced drug disposition and toxicology contract services provider, has introduced a novel microAmes screen that fully predicts the GLP regulatory Ames test (Salmonella/E. coli Mammalian Microsome Reverse Mutation Assay).

Evaluating compounds for mutagenic potential using the GLP regulatory Ames test is required for most small molecules prior to conducting first-in-human studies. Using approximately 5-10 mg of chemist bench sample, MBR can screen for Ames mutagenicity in two weeks or less.              

Current screens for mutagenicity use modified Ames bacterial tester strains, are run without a mammalian metabolic activation system, or are performed with just two of the five regulatory ICH-compliant tester strains often under conditions different than those of the regulatory Ames test.   These other screens therefore do not measure all the endpoints needed to fully assess the mutagenic potential of a compound or chemical series or require much larger compound amounts.   MBR's microAmes uses all five Salmonella and E. coli tester strains recommended by regulatory agencies and evaluates colony formation, cytotoxicity and compound precipitation using an agar format, factors that make this screen a highly predictive mutagenicity screen for the regulatory GLP Ames assay.

MBR also offers a microclastogenicity screen for predicting the regulatory GLP chromosomal aberration assay.   It provides the same speed, low compound requirements (10 mg), and cost advantages of the microAmes.

Download Full Article >